|
|
||||||||||||||||||||||||||||||||
Private PlacementsBy The Online Investor Staff, updated Wed., May. 1, 6:16 AM
Slide #12. DelMar Pharmaceuticals, Inc. — Private Placement
DelMar Pharmaceuticals is a clinical stage, biopharmaceutical company. Co. is developing VAL-083, a DNA-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and other solid tumors, including ovarian cancer and non-small cell lung cancer. Co. is also conducting open-label, biomarker driven studies in methyl guanine methyltransferase-unmethylated GBM. In addition to its clinical development activities in the United States, Co. has provided Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia and lung cancer. DelMar Pharmaceuticals is a clinical stage, biopharmaceutical company. Co. is developing VAL-083, a DNA-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and other solid tumors, including ovarian cancer and non-small cell lung cancer. Co. is also conducting open-label, biomarker driven studies in methyl guanine methyltransferase-unmethylated GBM. In addition to its clinical development activities in the United States, Co. has provided Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia and lung cancer.
Open the DMPI Page at The Online Investor (in a new window) » |
|